Akriti G. Jain, MD

Akriti G. Jain, MD, detailed the current unmet needs in polycythemia vera and myelofibrosis, including how to define disease modification.

Akriti G. Jain, MD, discusses factors that affect treatment sequencing with JAK inhibitors for the treatment of patients with myelofibrosis.

Akriti G. Jain, MD, details the treatment decision-making of JAK inhibitors for the treatment of patients with myelofibrosis.

Akriti G. Jain, MD, discusses the role of ruxolitinib for the treatment with polycythemia vera and myelofibrosis.

Akriti Jain, MD, discusses the phase 1b VERONA study of venetoclax plus azacitidine in higher-risk myelodysplastic syndromes.

Akriti Jain, MD, discusses unmet needs in patients with low- and high-risk myelodysplastic syndromes.

Akriti Jain, MD, discusses updated data from the phase 3 MEDALIST trial evaluating luspatercept for the treatment of anemic myelodysplastic syndromes.

Akriti Jain, MD, discusses the outcomes of the phase 3 COMMANDS trial in transfusion-dependent lower-risk myelodysplastic syndromes.